A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Study identifier:D1532C00004

ClinicalTrials.gov identifier:NCT00600496

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination with Standard Doses of Selected Chemotherapies to Patients with Advanced Solid Tumors

Medical condition

Breast Cancer

Phase

Phase 1

Healthy volunteers

No

Study drug

AZD6244, Dacarbazine, Erlotinib, Docetaxel, Temsirolimus

Sex

All

Actual Enrollment

140

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 14 Dec 2007
Primary Completion Date: 20 Aug 2010
Estimated Study Completion Date: 31 Dec 2024

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria